David Whiteman

2.4k total citations
72 papers, 1.6k citations indexed

About

David Whiteman is a scholar working on Physiology, Epidemiology and Genetics. According to data from OpenAlex, David Whiteman has authored 72 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Physiology, 14 papers in Epidemiology and 14 papers in Genetics. Recurrent topics in David Whiteman's work include Lysosomal Storage Disorders Research (27 papers), Trypanosoma species research and implications (13 papers) and Glycogen Storage Diseases and Myoclonus (10 papers). David Whiteman is often cited by papers focused on Lysosomal Storage Disorders Research (27 papers), Trypanosoma species research and implications (13 papers) and Glycogen Storage Diseases and Myoclonus (10 papers). David Whiteman collaborates with scholars based in United States, United Kingdom and Canada. David Whiteman's co-authors include Kathryn N. North, Alan Kimura, Barbara K. Burton, Melanie Pepin, Peter H. Byers, Paul Sabatier, Roberto Giugliani, Arian Pano, Paul Harmatz and Joseph Muenzer and has published in prestigious journals such as Neurology, Annals of Neurology and International Journal of Molecular Sciences.

In The Last Decade

David Whiteman

65 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Whiteman United States 24 585 340 332 296 250 72 1.6k
Sergey Ryazantsev Russia 24 843 1.4× 1.4k 4.0× 228 0.7× 333 1.1× 69 0.3× 189 2.8k
William Seltzer United States 26 262 0.4× 976 2.9× 492 1.5× 61 0.2× 52 0.2× 80 2.5k
Karine Tremblay Canada 25 213 0.4× 1.4k 4.1× 495 1.5× 174 0.6× 34 0.1× 71 3.1k
Peter Thijssen Belgium 23 211 0.4× 713 2.1× 193 0.6× 76 0.3× 42 0.2× 68 1.9k
James Connor Australia 25 87 0.1× 344 1.0× 337 1.0× 86 0.3× 88 0.4× 78 1.8k
J. J. Martin Belgium 21 281 0.5× 384 1.1× 47 0.1× 86 0.3× 49 0.2× 56 1.6k
Charles S. Abrams United States 39 373 0.6× 2.2k 6.3× 279 0.8× 147 0.5× 77 0.3× 115 4.5k
Hanan Hamamy Switzerland 23 115 0.2× 509 1.5× 678 2.0× 97 0.3× 161 0.6× 66 2.3k
Anne Summers Canada 25 55 0.1× 397 1.2× 636 1.9× 87 0.3× 90 0.4× 97 2.5k
Stanley Rothman United States 19 118 0.2× 309 0.9× 79 0.2× 141 0.5× 102 0.4× 105 1.9k

Countries citing papers authored by David Whiteman

Since Specialization
Citations

This map shows the geographic impact of David Whiteman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Whiteman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Whiteman more than expected).

Fields of papers citing papers by David Whiteman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Whiteman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Whiteman. The network helps show where David Whiteman may publish in the future.

Co-authorship network of co-authors of David Whiteman

This figure shows the co-authorship network connecting the top 25 collaborators of David Whiteman. A scholar is included among the top collaborators of David Whiteman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Whiteman. David Whiteman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Argueta, Christian, Oeystein Roed Brekk, Scott R. McDonnell, et al.. (2025). A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2/3 clinical trial and extension study of intrathecal idursulfase. Molecular Genetics and Metabolism. 144(3). 109055–109055. 1 indexed citations
2.
Muenzer, Joseph, Hernán Amartino, Roberto Giugliani, et al.. (2025). Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18 years: final report of the Hunter Outcome Survey. Molecular Genetics and Metabolism. 146(4). 109284–109284. 1 indexed citations
3.
Muenzer, Joseph, Hernán Amartino, Barbara K. Burton, et al.. (2024). Genotype–phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey. Molecular Genetics and Metabolism. 143(1-2). 108576–108576. 2 indexed citations
4.
Zhao, Peijun, et al.. (2024). Computer Vision for Gait Assessment in Cerebral Palsy: Metric Learning and Confidence Estimation. IEEE Transactions on Neural Systems and Rehabilitation Engineering. 32. 2336–2345. 1 indexed citations
5.
Muenzer, Joseph, Barbara K. Burton, Paul Harmatz, et al.. (2024). Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐ IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II. Journal of Inherited Metabolic Disease. 48(3). e12790–e12790. 1 indexed citations
6.
Groeschel, Samuel, Shanice Beerepoot, I. Krägeloh‐Mann, et al.. (2024). The effect of intrathecal recombinant arylsulfatase A therapy on structural brain magnetic resonance imaging in children with metachromatic leukodystrophy. Journal of Inherited Metabolic Disease. 47(4). 778–791.
7.
8.
Latzman, Robert D., Olivia Campagne, Meera E. Modi, et al.. (2024). Advancing clinical development for neuronopathic Hunter syndrome through a quantitatively‐driven reverse translation framework. Clinical and Translational Science. 17(4). e13776–e13776. 1 indexed citations
9.
Farah, Mohamed H., Christine í Dali, Samuel Groeschel, et al.. (2023). Effects of sulfatide on peripheral nerves in metachromatic leukodystrophy. Annals of Clinical and Translational Neurology. 11(2). 328–341. 4 indexed citations
10.
Yee, Karen S., et al.. (2023). Cognitive and adaptive behaviors associated with disease severity and genotype in patients with mucopolysaccharidosis II. Molecular Genetics and Metabolism. 140(3). 107652–107652. 1 indexed citations
11.
Whitley, Chester B., Maureen Cleary, Eugen Mengel, et al.. (2018). Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B. The Journal of Pediatrics. 197. 198–206.e2. 25 indexed citations
12.
Wiklund, Ingela, et al.. (2014). The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation. Quality of Life Research. 23(9). 2457–2462. 18 indexed citations
13.
14.
Wiklund, Ingela, et al.. (2012). The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: evaluation of measurement properties. Quality of Life Research. 22(4). 875–884. 13 indexed citations
15.
16.
Whiteman, David. (2009). Creating a "Green Bubble" on Campus: A Model for Programming in a Green Living-Learning Community. Scholar Commons (University of South Carolina). 36(1). 38.
17.
Whiteman, David, et al.. (2005). Privacy and Epidemiology: Report and Perspective on the NHMRC's Submission to the Review of the Privacy Act. 12(1). 4. 1 indexed citations
18.
Lorentz, Cindy Pham, Eric D. Wieben, Ayalew Tefferi, David Whiteman, & Gordon W. Dewald. (2002). Primer on Medical Genomics Part I: History of Genetics and Sequencing of the Human Genome. Mayo Clinic Proceedings. 77(8). 773–782. 15 indexed citations
19.
Prasad, C., Elizabeth J. Quackenbush, David Whiteman, & Bruce R. Korf. (1997). Limb anomalies in DiGeorge and CHARGE syndromes. American Journal of Medical Genetics. 68(2). 179–181. 20 indexed citations
20.
North, Kathryn N., David Whiteman, Melanie Pepin, & Peter H. Byers. (1995). Cerebrovascular complications in Ehlers‐Danlos syndrome type IV. Annals of Neurology. 38(6). 960–964. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sergey Ryazantsev Breakdown of academic impact, for papers by William Seltzer Breakdown of academic impact, for papers by Karine Tremblay Breakdown of academic impact, for papers by Peter Thijssen Breakdown of academic impact, for papers by James Connor Breakdown of academic impact, for papers by J. J. Martin Breakdown of academic impact, for papers by Charles S. Abrams Breakdown of academic impact, for papers by Hanan Hamamy Breakdown of academic impact, for papers by Anne Summers Breakdown of academic impact, for papers by Stanley Rothman
Rankless by CCL
2026